A phase III study (COSMIC-313) of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in patients (pts) with previously untreated advanced renal cell carcinoma (aRCC) of intermediate or poor risk

被引：0

作者：

Choueiri, Toni K.

Albiges, Laurence

Powles, Thomas

Scheffold, Christian

Wang, Fong

Motzer, Robert J.

机构：

[1] Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA

[2] Harvard Univ, Sch Med, Boston, MA USA

[3] Inst Gustave Roussy, Villejuif, France

[4] Queen Mary Univ London, Barts Canc Inst, London, England

[5] Exelixis Inc, Alameda, CA USA

[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 06期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS767

引用

页数：1

共 50 条

[31] A Randomized Phase II Study of Nivolumab Plus Ipilimumab Versus Standard of Care in Previously Untreated and Advanced Non-Clear Cell Renal Cell Carcinoma (Suniforecast)
Ahrens, Marit
Escudier, Bernard
Boleti, Ekaterini
Grimm, Marc-Oliver
Goupir, Marine Gross
Barthelemy, Pilippe
Gravis, Gwenaelle
Bedekes, Jens
Ivanyi, Philipp
Panic, Andrej
Zschaebitz, Stefanie
Neyrieru, Sylvie
Mellado, Begona
Biel, Anika
Wadell, Tom
Pablo Maroto, Jose
Retz, Margitta
Boegemann, Martin
Rottey, Sylvie
Haanen, John
Oosting, Sjoukje
Castellano, Daniel
Hartmann, Arndt
Bergmann, Lothar
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 226 - 226
[32] A randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST).
Ahrens, Marit
Escudier, Bernard
Boleti, Ekaterini
Grimm, Marc-Oliver
Gross-Goupil, Marine
Barthelemy, Philippe
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[33] A randomized phase II study of Nivolumab plus Ipilimumab versus standard of care in previously untreated and advanced non- clear cell renal cell carcinoma (SUNIFORECAST)
Bergmann, L.
Grimm, M. O.
Boleti, E. B.
Panic, A.
Gruellich, C.
Bedke, J.
Ahrens, M.
Lorch, A.
Negrier, S.
Ravaud, A.
Retz, M.
Boegemann, M.
Ivanyi, P.
Siemer, S.
Bathelemy, P.
Rottey, S.
Maroto, P.
Oosting, S.
Hartmann, A.
Escudier, B.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 285 - 285
[34] A phase III randomized open label study comparing bempegaldesleukin (NKTR-214) plus nivolumab to sunitinib or cabozantinib (investigator's choice) in patients with previously untreated advanced renal cell carcinoma.
Tannir, Nizar M.
Agarwal, Neeraj
Pal, Sumanta K.
Formiga, Maria Nirvana
Guo, Jun
George, Daniel J.
Tagliaferri, Mary Ann
Hannah, Alison L.
Zhang, Jenny Yanzhen
O'Keeffe, Bridget A.
Cho, Daniel C.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[35] A randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST).
Ahrens, Marit
Escudier, Bernard
Haanen, John B. A. G.
Boleti, Ekaterini
Goupil, Marine Gross
Grimm, Marc-Oliver
Negrier, Sylvie
Barthelemy, Philippe
Gravis, Gwenaelle
Ivanyi, Philipp
Bedke, Jens
Castellano, Daniel
Panic, Andrej
Mellado, Begona
Maroto-Rey, Pablo
Rottey, Sylvie
Zschaebitz, Stefanie
Deckbar, Dorothee
Hartmann, Arndt
Bergmann, Lothar
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[36] Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial
George, Daniel J.
Hessel, Colin
Halabi, Susan
Michaelson, M. Dror
Hahn, Olwen
Walsh, Meghara
Picus, Joel
Small, Eric J.
Dakhil, Shaker
Feldman, Darren R.
Mangeshkar, Milan
Scheffold, Christian
Morris, Michael J.
Choueiri, Toni K.
ONCOLOGIST, 2019, 24 (11): : 1497 - 1501
[37] Nivolumab plus cabozantinib (N plus C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Final follow-up results from the CheckMate 9ER trial.
Motzer, Robert J.
Escudier, Bernard
Burotto, Mauricio
Powles, Thomas
Apolo, Andrea B.
Bourlon, Maria T.
Shah, Amishi Yogesh
Porta, Camillo
Suarez, Cristina
Barrios, Carlos H.
Richardet, Martin Eduardo
Gurney, Howard
Kessler, Elizabeth R.
Tomita, Yoshihiko
Bedke, Jens
Rangwala, Fatima A.
Askelson, Margarita
Panzica, Julie
Fedorov, Viktor
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
[38] First-line Therapy of untreated advanced or metastatic Renal Cell Cancer Randomized, open, Phase-3 Study of Nivolumab in Combination with Cabozantinib versus Sunitinib in Participants with previously untreated, advanced or metastatic Renal Cell Cancer
Rexer, H.
Steiner, T.
Retz, M.
UROLOGE, 2018, 57 (12): : 1532 - 1533
[39] Prognostic value of the lung immune prognostic index in patients with untreated advanced renal cell carcinoma (aRCC) receiving nivolumab plus ipilimumab (N plus I) or sunitinib (SUN) in the CheckMate 214 trial.
Carril-Ajuria, Lucia
Motzer, Robert J.
Tannir, Nizar M.
McDermott, David F.
Hammers, Hans J.
Plimack, Elizabeth R.
Donskov, Frede
Rini, Brian I.
Jiang, Ruiyun
Lee, Chung-Wei
Desilva, Heshani
Albiges, Laurence
Roussy, Gustave
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[40] CheckMate 214: A phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in patients with previously untreated metastatic renal cell carcinoma.
Hammers, Hans J.
Plimack, Elizabeth R.
Sternberg, Cora
McDermott, David F.
Larkin, James M. G.
Ravaud, Alain
Rini, Brian I.
Sharma, Padmanee
Bhagavatheeswaran, Prabhu
Gagnier, Paul
Motzer, Robert
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

← 1 2 3 4 5 →